Study author Dr Dhruv Kazi said that the availability of cheap, effective generic versions of statins and ezetimibe makes the price of Praluent (alirocumab) harder to swallow. "Your additional ...

[Robinson JG. Clinical Lipid Management;455a] Alirocumab (Praluent, Regeneron) and evolocumab (Repatha, Amgen) are the two mAbs currently approved by the FDA; both received approval in 2015.

The final draft guidance recommends Sanofi's Praluent (alirocumab) and Amgen's Repatha (evolocumab) for adults with primary hypercholesterolaemia or mixed dyslipidaemia to help reduce risk of ...